Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 1

2(33.3%)

6Total

Phase 2(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02089334Phase 1Terminated

Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer

Role: lead

NCT02003092Phase 1Terminated

RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

Role: lead

NCT01028495Phase 2Completed

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Role: lead

NCT00839176Phase 2Completed

Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)

Role: lead

NCT01273376Phase 2Completed

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder

Role: lead

NCT00693056Phase 2Completed

Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)

Role: lead

All 6 trials loaded